Data expand clinical utility of deCODE's DNA-based risk tests for heart attack, AF and stroke

10:45-11:00am, Room 265-266, presentation number 4403, "Significant single nucleotide polymorphism associated with atrial fibrillation located on chromosome 4q25 in a whole genome association study and association with left atrial gene expression." Presenter: Mina Chung, Cleveland Clinic.

11:00-11:15am, Room 265-266, presentation number 4404, "Variation in the 4q25 chromosomal locus predicts new-onset atrial fibrillation after cardiac surgery." Presenter: Simon Brody, Brigham and Women's Hospital.

11:15-11:30am, Room 265-266, presentation number 4405, "Sequence variant for atrial fibrillation on chromosome 4q25 near the PITX2 gene increases risk for recurrent AF." Jeffrey Gulcher, deCODE genetics.

2:30-2:45pm, room 350-351, presentation number 5090, "Impact of adding a single allele in the 9p21 locus to traditional risk factors on risk classification for coronary heart disease and implications for lipid-modifying therapy in the white population of the Atherosclerosis Risk in Communities (ARIC) study." Presenter: C. M. Ballantyne, Baylor College of Medicine.

About deCODE

deCODE is a bio-pharmaceutical company developing drugs and DNA-based tests to improve the treatment, diagnosis and prevention of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer's disease and other conditions. deCODE is a global leader in human genetics, and has identified key variations in the genome (SNPs) conferring increased risk of major public health challenges from cardiovascular disease to cancer. Based upon these discoveries deCODE has brought to market a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases. Through its CLIA-registered laboratory, deCODE is offers deCODE T2™ for type 2 diabetes; deCODE AF™ for atrial fibrillation and stroke; deCODE MI™ for heart attack; deCODE ProCa™ for prostate cancer; deCODE Glaucoma™ for a major type of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at www.decode.com; on our diagnostics site at www.decodediagnostics.com; for our pioneering personal genome analysis service, integrating the genetic variants included in these tests and those linked to another twenty common diseases, at www.decodeme.com; and on our blog at www.decodeyou.com.